Vaccine News and Research

Latest Vaccine News and Research

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Rush University Medical Center has just enrolled the first U.S. patient in an international clinical trial testing a novel drug to treat certain kinds of melanoma, a deadly skin cancer that in its advanced stages currently has few effective treatments.

1 Dec 2010

Opinions: Obama's Global Fund pledge; harm reduction in Iran; HIV prevention; African development

There are some encouraging signs in the epic battle against AIDS and HIV infections. But those bright spots dim considerably in the face of the fact that about 7,100 people a day become infected.

30 Nov 2010

Gavi Alliance elects new chair to continue global immunisation efforts

Former Norwegian Minister of Health and current member of parliament Dagfinn Høybråten was unanimously elected by the GAVI Alliance Board as its new Chair, GAVI announced on the first day of its board meeting taking place in Kigali, the capital of Rwanda.

30 Nov 2010

Jiangsu Yanshen found liable for producing and selling inferior quality products

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen"), in which Simcere holds a 52.5% controlling stake, has been found liable for producing and selling inferior quality products by the People's Court of Tianning District, Changzhou City and was sentenced to a fine of RMB4.6 million.

30 Nov 2010

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of a case study report based on successful treatment of Progressive Multifocal Leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris' recombinant human interleukin-7 (CYT107) and CMX001, an investigational, oral broad-spectrum antiviral drug (Chimerix, Research Triangle Park, NC) in the Journal of Antimicrobial Chemotherapy.

30 Nov 2010

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway.

30 Nov 2010

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.

30 Nov 2010

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

Quintiles, the world's leading biopharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.

30 Nov 2010

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a long-term care or rehabilitation facility.

30 Nov 2010

Scientists uncover new regulatory mechanism in body's response to eliminate pathogens

A team of scientists from The Scripps Research Institute have uncovered a previously unknown regulatory mechanism in the body's response to eliminate pathogens, such as bacteria and viruses. The findings challenge a long-held dogma in the field of immunology and have potential implications for far-ranging topics from how vaccines should be administered to the origin of autoimmunity.

30 Nov 2010

University of Adelaide researcher leads collaboration for universal flu vaccine

A University of Adelaide researcher is leading a collaboration between Australia and Indonesia on the production of a universal flu vaccine. The frequent arising of new influenza strains represents the greatest challenge to health authorities as it renders currently available vaccines ineffective, says Dr Mohammed Alsharifi, the Head of the Vaccine Research Group at the School of Molecular and Biomedical Science, University of Adelaide.

30 Nov 2010

GAVI says pentavalent vaccine price to fall, but $3.7B still needed to vaccinate children in developing countries

The average price of a vaccine that protects children against five diseases is expected to "drop to $2.58 next year compared to the current average price of $2.97," the GAVI Alliance said Friday, Reuters reports. The group credits the expected price decline, which "represents a decrease of 30 percent over the last seven years," in part to an "increased demand for the pentavalent, or five-in-one vaccine," according to the news service (Kelland, 11/26).

30 Nov 2010

Haiti requires additional trained nurses, doctors to address cholera epidemic, U.N. official says

Haiti needs about 1,000 additional trained nurses and at least 100 more physicians to control the cholera epidemic, Valerie Amos, the U.N. undersecretary-general for humanitarian affairs, said during a recent visit to the capital of Port-au-Prince, Reuters reports.

30 Nov 2010

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.

29 Nov 2010

USPTO awards Immunitor key patent for viral vaccine

Immune Network Ltd., advises that its potential acquisition, Immunitor USA Inc., has been issued a key patent by the U.S. Patent and Trademark Office (USPTO).

29 Nov 2010

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

Accentia Biopharmaceuticals, Inc. today announced a strategic agreement with Baxter Healthcare Corporation to provide Accentia with the exclusive, worldwide right to purchase Baxter's cyclophosphamide, which is marketed under the brand name Cytoxan, for the treatment of designated autoimmune diseases including multiple sclerosis.

29 Nov 2010

HAL Allergy files MAA for PURETHAL Mites and SUBLIVAC FIX products at Paul-Ehrlich-Institute

HAL Allergy today announced that it has filed marketing authorization applications (MAA) for PURETHAL(R) Mites and SUBLIVAC(R) FIX Grasses, Trees, and Mites (incl. homologous group products) at the Paul-Ehrlich-Institute, the regulatory authority in Germany.

29 Nov 2010

SaneVax Team congratulates Senator for examining NCI ethical questions

In a letter addressed to U.S. Senator Charles Grassley, the SaneVax Team congratulated the senator on his recent efforts to examine ethical questions raised by National Cancer Institute (NCI) employees accepting extensive travel sponsored by private companies and identified two senior NCI scientists who knowingly promote unreliable human papillomavirus (HPV) tests for patient care, and the development/monitoring of genotype-specific HPV vaccines to promote an unproven virology-based cervical cancer prevention business agenda.

29 Nov 2010

Superantigens can disrupt immune system, can cause more illnesses

Superantigens, the toxins produced by staphylococcus bacteria, are more complex than previously believed, reveals a team of researchers from the University of Gothenburg in an article published today in the scientific journal Nature Communications. Their discovery shows that the body's immune system can cause more illnesses than realised.

29 Nov 2010

Whooping cough outbreak in Oklahoma

Oklahoma is witnessing an outbreak of whooping cough with more people falling ill. Health authorities are urging all people over 7 years of age to get vaccinated against the disease.

28 Nov 2010

Vaccine News and Research

Latest Vaccine News and Research

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Opinions: Obama's Global Fund pledge; harm reduction in Iran; HIV prevention; African development

Gavi Alliance elects new chair to continue global immunisation efforts

Jiangsu Yanshen found liable for producing and selling inferior quality products

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Scientists uncover new regulatory mechanism in body's response to eliminate pathogens

University of Adelaide researcher leads collaboration for universal flu vaccine

GAVI says pentavalent vaccine price to fall, but $3.7B still needed to vaccinate children in developing countries

Haiti requires additional trained nurses, doctors to address cholera epidemic, U.N. official says

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

USPTO awards Immunitor key patent for viral vaccine

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

HAL Allergy files MAA for PURETHAL Mites and SUBLIVAC FIX products at Paul-Ehrlich-Institute

SaneVax Team congratulates Senator for examining NCI ethical questions

Superantigens can disrupt immune system, can cause more illnesses

Whooping cough outbreak in Oklahoma

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in